Oncoinvent ASA (ONCIN) — Defensive Interval Ratio

Latest as of December 2025: 6 days

Oncoinvent ASA (ONCIN) has a Defensive Interval Ratio of 6 days as of December 2025. Defensive assets of Nkr992.00K (cash Nkr-, short-term investments Nkr-, receivables Nkr992.00K) cover 6 days of daily cash needs of Nkr158.79K/day. Check Oncoinvent ASA (ONCIN) tangible net worth to evaluate the tangible quality of the company's equity base.

Defensive Interval Ratio

6 days
Days of operational coverage

Defensive Assets

Nkr992.00K
Cash + ST Investments + Receivables

Daily Cash Need

Nkr158.79K
Current Liabilities ÷ 365

Current Liabilities

Nkr57.96 Million
NOK

Oncoinvent ASA Defensive Interval Ratio (2021–2025)

This chart shows how Oncoinvent ASA's Defensive Interval Ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 6 days, meaning defensive assets of Nkr992.00K can fund 6 days of operations without new revenue. Also explore Oncoinvent ASA (ONCIN) equity growth momentum to track the company's year-over-year net asset growth rate.

Annual Defensive Interval Ratio for Oncoinvent ASA (2021–2025)

The table below presents the year-by-year Defensive Interval Ratio for Oncoinvent ASA from 2021 to 2025, covering 5 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see Oncoinvent ASA market cap and net worth.

Year DIR (days) Defensive Assets (NOK) Daily Cash Need Cash ST Investments Change (days)
2025 1125 days Nkr178.60 Million Nkr158.79K/day Nkr177.60 Million Nkr- ▲ +239 days
2024 886 days Nkr140.60 Million Nkr158.74K/day Nkr140.16 Million Nkr- ▼ -333 days
2023 1218 days Nkr156.42 Million Nkr128.38K/day Nkr156.42 Million Nkr- ▲ +512 days
2022 706 days Nkr150.80 Million Nkr213.52K/day Nkr150.80 Million Nkr- ▲ +706 days
2021 0 days Nkr0.00 Nkr177.72K/day Nkr- Nkr-
DIR = (Cash + Short-term Investments + Net Receivables) / (Daily Cash Expenses)